[HTML][HTML] Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell …
M Reck, EB Garon, L Paz-Ares, S Ponce, JC Jaime… - Clinical lung cancer, 2018 - Elsevier
Background Despite the likelihood of an initial response to an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non–small-cell lung cancer …
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non–small-cell lung cancer …
[HTML][HTML] Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell …
M Reck, EB Garon, L Paz-Ares, S Ponce… - Clinical Lung …, 2018 - clinical-lung-cancer.com
Background Despite the likelihood of an initial response to an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non–small-cell lung cancer …
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non–small-cell lung cancer …
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung …
M Reck, EB Garon, L Paz-Ares, S Ponce… - Clinical Lung …, 2017 - europepmc.org
Background Despite the likelihood of an initial response to an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non-small-cell lung cancer …
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non-small-cell lung cancer …
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell Lung …
M Reck, EB Garon, L Paz-Ares… - Clinical Lung …, 2018 - okayama.elsevierpure.com
抄録 We conducted safety, exposure, and progression-free survival analyses of patients in
part A (phase 1b) of RELAY, a randomized, double-blind, phase Ib/III study investigating …
part A (phase 1b) of RELAY, a randomized, double-blind, phase Ib/III study investigating …
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung …
M Reck, EB Garon, L Paz-Ares, S Ponce… - Clinical lung …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Despite the likelihood of an initial response to an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non-small-cell lung cancer …
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non-small-cell lung cancer …
[引用][C] Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell Lung …
M Reck, EB Garon, L Paz-Ares, S Ponce, JC Jaime… - Clinical Lung …, 2018 - cir.nii.ac.jp
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in
Previously Untreated EGFR -Mutant Metastatic Non–Small-Cell Lung Cancer (RELAY): Phase …
Previously Untreated EGFR -Mutant Metastatic Non–Small-Cell Lung Cancer (RELAY): Phase …
[PDF][PDF] Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic None Small-Cell Lung …
M Reck, EB Garon, L Paz-Ares, S Ponce… - Clinical Lung …, 2018 - academia.edu
We conducted safety, exposure, and progression-free survival analyses of patients in part A
(phase 1b) of RELAY, a randomized, double-blind, phase Ib/III study investigating …
(phase 1b) of RELAY, a randomized, double-blind, phase Ib/III study investigating …
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell Lung …
M Reck, EB Garon, L Paz-Ares… - Clinical Lung …, 2018 - okayama.elsevierpure.com
We conducted safety, exposure, and progression-free survival analyses of patients in part A
(phase 1b) of RELAY, a randomized, double-blind, phase Ib/III study investigating …
(phase 1b) of RELAY, a randomized, double-blind, phase Ib/III study investigating …